期刊文献+

内皮缩血管肽A受体拮抗剂ETP-508对内皮缩血管肽1诱导的心肌细胞肥厚的作用 被引量:3

Effects of an endothelin A-receptor antagonist ETP-508 on endothelin-1-induced cardiomyocyte hypertrophy
下载PDF
导出
摘要 目的观察内皮缩血管肽(ET)A受体拮抗剂ETP-508对ET-1诱导的心肌细胞肥厚的作用。方法心肌细胞用ET-1(10nmol·L-1)或ET-1+ETP-508(10μmol·L-1)处理24h,分别采用光学显微镜、[3H]亮氨酸掺入、激光扫描共聚焦显微镜和RT-PCR技术方法观察ETP-508对心肌细胞表面积、蛋白质合成、肌原纤维肌节重新组装和基因表达的影响。结果ET-110nmol·L-1诱导心肌细胞表面积和[3H]亮氨酸掺入增加,胚胎基因心钠素和肌球蛋白轻链2的mRNA表达增加,肌原纤维节重新形成;ETP-50810μmol·L-1可显著抑制ET-1诱导的心肌细胞表面积和[3H]亮氨酸掺入增加,抑制率分别达56%和46%;并显著减弱肌原纤维节的重新形成和胚胎基因的再表达。结论ETP-508对ET-1诱导的乳大鼠心肌细胞肥厚有显著的阻断作用。 AIM To observe the effects of endothelin A-receptor antagonist ETP-508 on cardiomyocyte hypertrophy-induced by endothe- lin-1 (ET-1) in neonatal rat cardiomyocytes. METHODS Cardiomyocytes were exposed to ET-1 ( 10nmol·L^-1 ) or ET-1 combined with ETP-508 ( 10 μmol·L^-1) treatment for 24 h. Cardiomyocytes surface area, incorporation of [ 3H ] leucine, sarcomere reorganization and gene expression were evaluated by optical microscopy, [ 3H ] leucine incorporation, laser scanning confocal microscopy and RT-PCR, respectively. RESULTS Increases in myo- eyte surface area and incorporation of [ 3H ] leucine, mRNA expression of embryo genes atrial natriuretic factor and myoglobin light chain-2, and sarcomere reorganization were observed in the model of cardiomyocytes hypertrophy induced by ET-1 10nmol·L^-1. ETP-508 10μmol·L^-1 significantly inhibited ET-1 induced increases in myocyte surface area and [ 3H ] leucine uptake, and the inhibition rate was 56% and 46%, respectively. Furthermore, ETP-508 significantly attenuated sarcomere reorgani- zation and embryo gene re-expression. CONCLUSION ETP-508 remarkably abolishes ET-l-induced rat neonatal cardiomyocytes hypertrophy.
出处 《中国药理学与毒理学杂志》 CAS CSCD 北大核心 2009年第1期23-28,共6页 Chinese Journal of Pharmacology and Toxicology
基金 国家高技术研究发展计划资助项目(2006AA020601)~~
关键词 受体 内皮缩血管肽 内皮缩血管肽受体拮抗剂 ETP-508 心肌病 肥厚性 肌细胞 心脏 receptors, endothelin endothelin receptor antagonists ETP-508 cardiomyopathy, hypertrophic myocytes, cardic
  • 相关文献

参考文献14

  • 1Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells[J]. Nature, 1988, 332(6163):411-415.
  • 2Motte S, McEntee K, Naeije R. Endothelin receptor antagonists[J]. Pharmacol Ther, 2006, 10(3):386-414.
  • 3Galié N, Manes A, Branzi A. The endothelin system in pulmonary arterial hypertension[J]. Cardiovasc Res, 2004, 61(2):227-237.
  • 4Komuro I. Molecular mechanism of cardiac hypertrophy and development[J]. Jpn Circ J, 2001, 65(5):353-358.
  • 5Frey N, Katus HA, Olson EN, Hill JA. Hypertrophy of the heart: a new therapeutic target[J]? Circulation, 2004, 109(13):1580-1589.
  • 6McKinsey TA, Kass DA. Small-molecule therapies for cardiac hypertrophy: moving beneath the cell surface[J]. Nat Rev Drug Discov, 2007, 6(8):617-635.
  • 7Ito H, Hirata Y, Adachi S, Tanaka M, Tsujino M, Koike A, et al. Endothelin-1 is an autocrine/paracrine factor in the mechanism of angiotensin Ⅱ-induced hypertrophy in cultured rat cardiomyocytes[J]. J Clin Invest, 1993, 92(1):398-403.
  • 8Yamazaki T, Komuro I, Kudoh S, Zou Y, Shiojima I, Hiroi Y, et al. Endothelin-1 is involved in mechanical stress-induced cardiomyocyte hypertrophy[J]. J Biol Chem, 1996, 271(6):3221-3228.
  • 9Dong JJ, Yang N, Liang YJ, Wu P, Li X, Liu KL. Design and structure-activity relationship of a novel endothelin receptor A tripeptide antagonists[J]. Inter J Pep Res Ther, 2005, 11(2):125-129.
  • 10Gupta S, Das B, Sen S. Cardiac hypertrophy: mechanisms and therapeutic opportunities[J]. Antioxid Redox Signal, 2007, 9(6):623-652.

同被引文献78

引证文献3

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部